You are now using a guest account at UpDown that will expire in 7 days on November 30. Sign up below to join the site and save your portfolio.
Note: If you already have an UpDown account , please log in.

DENDREON CORP (DNDN) 28.01 -$0.04 (-0.14%) 04:57AM (15 mins delay)

Dendreon: Charting the Course to Big Profits

Jun 10, 2009 - 6:46 AM EDT

Jamie Moye submits:

While the number of North American men being diagnosed annually with prostate cancer has seen a slight decline during the past decade, this trend will likely reverse in the coming years due to the aging of the Baby Boomers, who are just entering the demographic most susceptible to the disease.

However, a groundbreaking new treatment for the disease will likely receive U.S. Food and Drug Administration ((FDA)) approval and become widely available just as the first Baby Boomers reach 65 in 2010. While the new treatment is not a “cure-all,” it offers a new possibility for a longer life to those diagnosed with the almost-always fatal advanced form of the disease.

Complete Story »

Source: Seeking Alpha (Jun 10, 2009 - 6:46 AM EDT)